Q3 EPS Estimate for Apogee Therapeutics Decreased by Analyst

Key Points

• Wedbush has revised its earnings estimates for Apogee Therapeutics, projecting a loss of ($1.21) per share for Q3 2025, which is a decline from its previous estimate of ($0.96).
• The company reported a loss of ($1.13) per share in its most recent quarterly earnings, falling short of the consensus estimate of ($1.03) by ($0.10).
• Despite the earnings cut, Wedbush maintains an "Outperform" rating with a price target of $90.00 for Apogee Therapeutics, which has a consensus buy rating among analysts.

Apogee Therapeutics Inc. (NASDAQ:APGE - Free Report) - Investment analysts at Wedbush reduced their Q3 2025 earnings estimates for Apogee Therapeutics in a research report issued to clients and investors on Monday, August 11th. Wedbush analyst D. Nierengarten now forecasts that the company will earn ($1.21) per share for the quarter, down from their previous forecast of ($0.96). Wedbush has a "Outperform" rating and a $90.00 price target on the stock. The consensus estimate for Apogee Therapeutics' current full-year earnings is ($3.09) per share. Wedbush also issued estimates for Apogee Therapeutics' Q4 2025 earnings at ($1.24) EPS, FY2025 earnings at ($4.53) EPS, Q1 2026 earnings at ($1.27) EPS, Q2 2026 earnings at ($1.18) EPS, Q3 2026 earnings at ($1.18) EPS, Q4 2026 earnings at ($1.13) EPS, FY2026 earnings at ($4.75) EPS, FY2027 earnings at ($4.75) EPS, FY2028 earnings at ($6.13) EPS and FY2029 earnings at ($5.99) EPS.

Apogee Therapeutics (NASDAQ:APGE - Get Free Report) last announced its earnings results on Monday, August 11th. The company reported ($1.13) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.03) by ($0.10).

APGE has been the topic of several other reports. BTIG Research increased their target price on shares of Apogee Therapeutics from $100.00 to $115.00 and gave the stock a "buy" rating in a research note on Monday, July 7th. Citigroup reiterated a "buy" rating on shares of Apogee Therapeutics in a research report on Monday, July 7th. Guggenheim reiterated a "buy" rating and set a $116.00 price target on shares of Apogee Therapeutics in a research report on Wednesday, July 2nd. Finally, Zacks Research downgraded Apogee Therapeutics from a "strong-buy" rating to a "hold" rating in a research report on Thursday, August 14th. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company. According to data from MarketBeat, Apogee Therapeutics has a consensus rating of "Moderate Buy" and a consensus target price of $99.00.

Apogee Therapeutics Stock Down 2.1%

Apogee Therapeutics stock traded down $0.7850 during midday trading on Thursday, reaching $36.1150. The stock had a trading volume of 124,319 shares, compared to its average volume of 742,284. Apogee Therapeutics has a 12 month low of $26.20 and a 12 month high of $63.50. The firm's 50-day moving average price is $40.02 and its 200 day moving average price is $37.85. The firm has a market capitalization of $1.67 billion, a PE ratio of -8.74 and a beta of 1.43.

Insider Activity

In other news, insider Carl Dambkowski sold 10,090 shares of the company's stock in a transaction that occurred on Wednesday, July 2nd. The shares were sold at an average price of $45.09, for a total value of $454,958.10. Following the transaction, the insider owned 238,998 shares in the company, valued at approximately $10,776,419.82. This represents a 4.05% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. Insiders have sold a total of 15,540 shares of company stock valued at $658,625 in the last 90 days. Corporate insiders own 42.77% of the company's stock.

Institutional Trading of Apogee Therapeutics

Several large investors have recently added to or reduced their stakes in APGE. Nisa Investment Advisors LLC lifted its holdings in Apogee Therapeutics by 99.2% during the second quarter. Nisa Investment Advisors LLC now owns 769 shares of the company's stock valued at $33,000 after purchasing an additional 383 shares in the last quarter. Brooklyn Investment Group bought a new stake in Apogee Therapeutics in the first quarter worth $42,000. GF Fund Management CO. LTD. bought a new stake in Apogee Therapeutics in the fourth quarter worth about $43,000. AlphaQuest LLC bought a new stake in Apogee Therapeutics in the first quarter worth about $43,000. Finally, Mirae Asset Global Investments Co. Ltd. increased its stake in Apogee Therapeutics by 18.0% in the second quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,779 shares of the company's stock worth $77,000 after purchasing an additional 272 shares during the period. 79.04% of the stock is currently owned by institutional investors.

Apogee Therapeutics Company Profile

Apogee Therapeutics, Inc, through its subsidiary, operates as a biotechnology company that develops biologics for the treatment of atopic dermatitis (AD), asthma, chronic obstructive pulmonary disease (COPD), and related inflammatory and immunology indications. The company primarily develops APG777, a subcutaneous (SQ) extended half-life monoclonal antibody (mAb) for AD; and APG808, an SQ extended half-life mAb for COPD.